🇯🇵·11h agoIndustry
China’s National Medical Products Administration Accepts Biologics License Application for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Muscle-Invasive Bladder Cancer
Publisher
A
Astellas Pharma
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Astellas Pharma
- Region
- Japan
- Scope
- Industry
- Published
- July 7, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on newsroom.astellas.com
Leave the platform to read the original full article on the publisher site.
Source: Astellas Pharma
Scope: Industry
Related coverage
More related coverage
Hyman, Phelps & McNamara (FDA Law)/3h ago
Coming Soon: Proposed Rule to Remove “Adequate Provision” (and Ban DTC TV Ads?)
Roche Newsroom/9h ago
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Natco Pharma/14h ago
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Natco Pharma/14h ago